CN104013959A - 逆转录抑制剂和免疫抗体细胞三联合疗法 - Google Patents

逆转录抑制剂和免疫抗体细胞三联合疗法 Download PDF

Info

Publication number
CN104013959A
CN104013959A CN201410219603.0A CN201410219603A CN104013959A CN 104013959 A CN104013959 A CN 104013959A CN 201410219603 A CN201410219603 A CN 201410219603A CN 104013959 A CN104013959 A CN 104013959A
Authority
CN
China
Prior art keywords
reverse transcription
transcription inhibitor
immunity
antibody
antibody cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201410219603.0A
Other languages
English (en)
Inventor
郭和友
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chen Zhe
Original Assignee
郭和友
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 郭和友 filed Critical 郭和友
Priority to CN201410219603.0A priority Critical patent/CN104013959A/zh
Publication of CN104013959A publication Critical patent/CN104013959A/zh
Withdrawn legal-status Critical Current

Links

Abstract

本发明涉及一种逆转录抑制剂和免疫抗体细胞三联合疗法，目前公知的治疗逆转录病毒的方法只是逆转录抑制剂，效果不好，本声明的目的是；更好的治疗逆转录病毒本发明的解决其技术问题采用的方案是；从病人体内提取免疫细胞和抗体，然后把免疫细胞和抗体双扩增后注射通过氧气培养和隔带代培养提高抗体的力量同时数量，就象军队打仗一个兵增加1万兵，同时加强兵战斗力，还有增加生产兵力的机构。同时加上逆转录抑制剂，逆转录抑制剂和免疫，抗体细胞三联合疗法本发明的好处是；免疫细胞和抗体双扩增，提高治疗效果。

Description

逆转录抑制剂和免疫抗体细胞三联合疗法
技术领域
本发明涉及一种逆转录抑制剂和免疫抗体细胞三联合疗法 
技术背景
目前公知的治疗逆转录病毒的方法只是逆转录抑制剂.效果不好. 
发明内容
本发明的目的是；更好的治疗逆转录病毒。 
本发明的解决其技术问题采用的方案是；从病人体内提取免疫细胞和抗体，然后把免疫细胞和抗体双扩增后注射通过氧气培养和隔带代培养提高抗体的力量同时数量，就象军队打仗一个兵增加1万兵，同时加强兵战斗力，还有增加生产兵力的机构。同时加上逆转录抑制剂.逆转录抑制剂和免疫，抗体细胞三联合疗法 
本发明的好处是；免疫细胞和抗体双扩增，提高治疗效果。 
下面结合附图对本发明作进一步说明 
图1是，一种逆转录抑制剂和免疫疗联合疗法 
图中  1病人  2病人的免疫细胞和抗体  3免疫细胞  4抗体  5体外扩增  6培养扩增氧气7增活和增量的免疫细胞  8增活和增量的抗体  9回注  10人体加氧11逆转录抑制剂 
在图1中先从病人(1)体内病人的免疫细胞和抗体(2)提取出免疫细胞(3)抗体(4)通过培养扩增氧气(6)注入体外扩增(5)同时来增活和增量的免疫细胞(7)增活和增量的抗体(8)，然后回注(9)病人(1)体内，同时人体加氧(10)就是吸氧方式来增加治疗效果，同时加上逆转录抑制剂(11)抗病毒。 

Claims (3)

1.一种逆转录抑制剂和免疫抗体细胞三联合疗法，其特征是；从病人体内提取免疫细胞和抗体，然后把免疫细胞和抗体双扩增后注射通过氧气培养和隔带代培养提高抗体的力量同时数量。
2.根据权利要求书(1)所述的一种逆转录抑制剂和免疫抗体细胞三联合疗法，其特征是；同时加上逆转录抑制剂，逆转录抑制剂和免疫，抗体细胞三联合疗法。
3.根据权利要求书(1)所述的一种逆转录抑制剂和免疫抗体细胞三联合疗法，其特征是；扩增可以使用PCR或培养方法。 
CN201410219603.0A 2014-05-21 2014-05-21 逆转录抑制剂和免疫抗体细胞三联合疗法 Withdrawn CN104013959A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410219603.0A CN104013959A (zh) 2014-05-21 2014-05-21 逆转录抑制剂和免疫抗体细胞三联合疗法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410219603.0A CN104013959A (zh) 2014-05-21 2014-05-21 逆转录抑制剂和免疫抗体细胞三联合疗法

Publications (1)

Publication Number Publication Date
CN104013959A true CN104013959A (zh) 2014-09-03

Family

ID=51431138

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410219603.0A Withdrawn CN104013959A (zh) 2014-05-21 2014-05-21 逆转录抑制剂和免疫抗体细胞三联合疗法

Country Status (1)

Country Link
CN (1) CN104013959A (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707814A (en) * 1991-11-01 1998-01-13 The Regents Of The University Of California CD8+ cell antiviral factor
WO2000069255A1 (en) * 1999-05-14 2000-11-23 The Regents Of The University Of California Anti-inflammatory therapy for inflammatory mediated infection
WO2003070270A1 (en) * 2002-02-20 2003-08-28 Immunaid Pty Ltd Strategy for retroviral immunotherapy
CN1469746A (zh) * 2000-08-18 2004-01-21 逆转录病毒免疫疗法
CN102344492A (zh) * 2010-08-03 2012-02-08 西安杰诺瓦生物科技有限公司 一种双向特异性配体靶向逆转录病毒的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707814A (en) * 1991-11-01 1998-01-13 The Regents Of The University Of California CD8+ cell antiviral factor
WO2000069255A1 (en) * 1999-05-14 2000-11-23 The Regents Of The University Of California Anti-inflammatory therapy for inflammatory mediated infection
CN1469746A (zh) * 2000-08-18 2004-01-21 逆转录病毒免疫疗法
WO2003070270A1 (en) * 2002-02-20 2003-08-28 Immunaid Pty Ltd Strategy for retroviral immunotherapy
CN102344492A (zh) * 2010-08-03 2012-02-08 西安杰诺瓦生物科技有限公司 一种双向特异性配体靶向逆转录病毒的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
S. PHOGAT等: "Inhibition of HIV‐1 entry by antibodies: potential viral and cellular targets", 《J INTERN MED.》 *
李琼等: "逆转录酶和蛋白酶抑制剂在治疗艾滋病中的应用分析", 《中国卫生产业》 *
莫冰等: "免疫调节治疗鼠逆转录病毒导致获得性免疫缺陷综合征", 《中国免疫学杂志》 *

Similar Documents

Publication Publication Date Title
WO2012094679A3 (en) Compositions and methods for delivery of high-affinity oxygen binding agents to tumors
WO2011002721A8 (en) Non-human mammal model of human hematopoietic cancer
ATE490470T1 (de) Therapieverfahren
JP2016513460A5 (zh)
WO2013039861A3 (en) Engineered nucleic acids and methods of use thereof
PL1885382T3 (pl) Sposoby stosowania komórek pochodzących z tkanki tłuszczowej w leczeniu stanów układu sercowo-naczyniowego
WO2014183033A3 (en) G-csf for use in treating or preventing a disease associated with aging in a patient, for administration with a stem-cell containing composition and/or an electromagnetic signal
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
RU2015143513A (ru) Микровезикула и способ ее получения
EA201591522A1 (ru) Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов
BRPI0610968A2 (pt) composição de sangue de cordão umbilical, e, métodos para tratar uma doença maligna ou distúrbio benigno associado com o sistema hemoatopoiético e para preparar uma composição de sangue umbilical
Sano et al. Cardiac stem cell therapy: Does a newborn infant's heart have infinite potential for stem cell therapy?
SG11201900986YA (en) Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
WO2014100746A3 (en) Tspan 33 is a candidate for antibody targeted therapy for the treatment of b cell hodgkin lymphomas
CN104013959A (zh) 逆转录抑制剂和免疫抗体细胞三联合疗法
MX2021003798A (es) Terapia con celulas de placenta humana y celulas hematopoyeticas.
JP2012507997A5 (zh)
EP2345428A3 (en) Preparation method of prostate tumor-targeted double-regulated oncolytic adenovirus expressing superantigen gene
CN204070763U (zh) 磁疗鞋
Zoufaly et al. High Prevalence of Hepatitis B and Syphilis Co-Infection among Newly Diagnosed HIV Patients in the North West Region of Cameroon
CN103255106A (zh) 亚健康治疗用自体造血干细胞技术
Raoufinia et al. Collaboration of high efficient siRNA and nanodelivery technology in cancer combating
RU2010121106A (ru) Способ лечения рака легкого
CN103088026A (zh) 抗乙型肝炎病毒人工miRNA及其组合

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20170523

Address after: 518126, room 715, block A, innovation center, two road, Baoan District, Guangdong, Shenzhen

Applicant after: Chen Zhe

Applicant after: Guo Heyou

Address before: 473132 east house, 1 floor, unit 40, building 1, Taishan District, Nanyang oilfield, Henan

Applicant before: Guo Heyou

WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20140903